Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.
Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.
Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.
Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.
Registry search results
Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-08 11:16 UTC. Counts are registry matches, not unique peptides or a worldwide total.
Phase not reported / not applicableCompletedOBSERVATIONAL
Start: 2024-06-10. Completion: 2025-06-10 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Data collection (other)
Blood sampling (other)
Questionnaires (other)
Where the study takes place — 14 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Bondy, France
Explore the world’s study registries
These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.
Start: 2024-07-01. Completion: 2028-06-30 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Semaglutide (drug) — also listed as: Ozempic
Placebo (drug) — also listed as: Saline
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Health Promotion Research Center Oklahoma City, Oklahoma, United States Site recruitment: Recruiting
Start: 2025-08-31. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
RAY1225 (drug)
Semaglutide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Peking University People's Hospital Beijing, Heibei, China Site recruitment: Not reported
Start: 2022-10-07. Completion: 2024-05-13 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Semaglutide (drug)
Sham/placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
University of North Carolina Chapel Hill, North Carolina, United States Site recruitment: Not reported
Start: 2026-01-01. Completion: 2031-09-30 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Semaglutide (Rybelsus®) combined with other interventions (drug) — also listed as: Candesartan, multivitamin-mineral tablets containing vitamin D and calcium, increased oral hygiene and a tooth lozenge (CariGuard®), Combination group
Placebo (other)
Semaglutide (Rybelsus®) (drug)
Where the study takes place — 0 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
The registry does not list facilities in this record. This does not mean the study has no sites.
Obesity in Diabetes; Obesity/Therapy; Type 1 Diabetes Mellitus (T1DM); Insulin Sensitivity/Resistance; Semaglutide; Lipidomics; Metabolomics; Weight Loss; Glycemic Control for Diabetes Mellitus
Sponsor
Nordsjaellands Hospital
Countries with listed sites
Denmark
Registry dates and results
Start: 2025-10. Completion: 2028-06 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Semaglutide 2.4mg (drug) — also listed as: Active semaglutide
Semaglutide placebo (drug) — also listed as: Placebo semaglutide
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Nordsjaellands Hospital Hillerød, Denmark, Denmark Site recruitment: Not reported
Alcohol Abuse; Alcohol Addiction; Alcohol Dependence; Alcohol Use Disorder
Sponsor
Psychiatric Centre Rigshospitalet
Countries with listed sites
Denmark
Registry dates and results
Start: 2023-06-13. Completion: 2025-07-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Semaglutide Injectable Product (drug) — also listed as: Wegovy
Placebo (drug) — also listed as: BD Posiflush (saline)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Psychiatric Center Copenhagen, Frederiksberg Hospital Frederiksberg, Denmark Site recruitment: Not reported
Start: 2023-05-31. Completion: 2024-01-04 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
HS-20094 5mg (drug) — also listed as: HS-20094 injection 5mg
HS-20094 10mg (drug) — also listed as: HS-20094 injection 10mg
HS-20094 15mg (drug) — also listed as: HS-20094 injection 15mg
HS-20094 20mg (drug) — also listed as: HS-20094 injection 20mg
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Peking University First Hospital Beijing, Beijing Municipality, China Site recruitment: Not reported
Start: 2024-09-22. Completion: 2025-02-12 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Ozempic® (drug)
HDG1901 (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
The Second Hospital of Anhui Medical University Hefei, Anhui, China Site recruitment: Not reported
Start: 2024-12-17. Completion: 2025-08 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Metformin (drug)
Rapamycin (drug)
Naltrexone (drug)
Vitamin C (dietary_supplement)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
AgelessRx Chicago, Illinois, United States Site recruitment: Recruiting
Start: 2024-11-01. Completion: 2025-12-01 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
GLP-1 (drug) — also listed as: Semaglutide
Placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
AgelessRx Ann Arbor, Michigan, United States Site recruitment: Not reported
Start: 2026-04-01. Completion: 2031-04-01 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Wegovy ® (drug)
Placebo (drug)
Where the study takes place — 0 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
The registry does not list facilities in this record. This does not mean the study has no sites.
Start: 2023-09-20. Completion: 2025-02-21 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Ozempic® (drug)
HDG1901 (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Beijing Hospital Beijing, Beijing Municipality, China Site recruitment: Not reported
Start: 2025-10-01. Completion: 2028-07-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Semaglutide 1.0 mg (drug)
Semaglutide 0.5 mg (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Taipei Veterans General Hospital Taipei, Taiwan Site recruitment: Not reported
Start: 2024-01-01. Completion: 2025-06-25 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Oral semaglutide (drug)
subcutaneous semaglutide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Policlinico Paolo Giaccone Palermo, Italy Site recruitment: Not reported
Start: 2023-09-28. Completion: 2024-03-27 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Semaglutide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Altasciences Clinical Company, Inc Montreal, Quebec, Canada Site recruitment: Not reported
Start: 2020-09-10. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Semaglutide (drug) — also listed as: Ozempic
Dapagliflozin (drug) — also listed as: Forxiga
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Anders Rosengrentest Malmö, Skåne County, Sweden Site recruitment: Not reported
Start: 2024-02-23. Completion: 2025-05-14 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
semaglutide injection (HD1916) (drug)
Ozempic® (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangdong, Guangdong, China Site recruitment: Not reported
Start: 2023-12-18. Completion: 2025-04-30 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
semaglutide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Leumit Health ccare system Hadera, Israel Site recruitment: Not reported
Start: 2025-08-01. Completion: 2029-02-01 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
F027 (drug)
Ozempic® (drug)
Where the study takes place — 0 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
The registry does not list facilities in this record. This does not mean the study has no sites.
Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.
